Abstract: Disclosed is a process for the preparation of Enzalutamide comprising the reaction (Scheme 2), wherein R can be alkyl, aryl, aryl-alkyl or heterocyclyl.

Abstract: Disclosed is a process for the preparation of Enzalutamide comprising the reaction (Scheme 2), wherein R can be alkyl, aryl, aryl-alkyl or heterocyclyl.

Abstract: A process for the preparation of Rotigotine (1) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7, 8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.

Abstract: A process for the preparation of Rotigotine (1) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)—N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.

Abstract: A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II). The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxynaphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.

Abstract: A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.

Abstract: The invention concerns a 3-alkylated crystallized (1R,4S)-p-menthan-(3)-ol derivative, of formula A or B, wherein: either when R<2> represents hydrogen or a methyl radical, R<1> represents a —(CH2)n-OH where n can be 1, 2 and 3, or when R<2> represents a hydroxy radical, R<1> represents a methyl radical or a —(CH2)n-OH group where n can be 1, 2 and 3. The invention also concerns methods for preparing same, and perfume, cosmetic or food compositions containing said derivative.

Abstract: The invention relates to a process for the preparation of duloxetine (1a), comprising the reaction between 1-fluoronaphthalene and 3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol in the presence of 1,3-dimethyl-2-oxo-hexahydropyrimidine (DMPU) as the solvent; a method for the identification of duloxetine enantiomers and for the determination of its optical purity is also disclosed.

Abstract: The invention concerns a 3-alkylated crystallized (1R,4S)-p-menthan-(3)-ol derivative, of formula A or B, wherein: either when R<2> represents hydrogen or a methyl radical, R<1> represents a —(CH2)n-OH where n can be 1, 2 and 3, or when R<2> represents a hydroxy radical, R<1> represents a methyl radical or a —(CH2)n-OH group where n can be 1, 2 and 3. The invention also concerns methods for preparing same, and perfume, cosmetic or food compositions containing said derivative.

Abstract: The invention relates to a process for the preparation of duloxetine (1a), comprising the reaction between 1-fluoronaphthalene and 3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol in the presence of 1,3-dimethyl-2-oxo-hexahydropyrimidine (DMPU) as the solvent; a method for the identification of duloxetine enantiomers and for the determination of its optical purity is also disclosed.

Abstract: Tazarotene is prepared by deoxygenation of the corresponding S-oxide, in turn obtained according to two alternative synthetic pathways.

Abstract: Tazarotene is prepared by deoxygenation of the corresponding S-oxide, in turn obtained according to two alternative synthetic pathways.

Abstract: A method for determining the origin of substances with biological, biochemical and nutritional physiological relevance and distinguishing them from synthetic analogs using their relative positional oxygen or hydrogen isotope ratios (&dgr;18O value and &dgr;2H value), in which—based on the fact that for organic compounds there are at least two different primary or secondary sources for these elements, each with different isotope values, and the incorporation of these elements is accompanied by different, but characteristic effects—the positional &dgr;18O values or &dgr;2H values are individually determined in the substances to be tested and they are compared with the values expected from biosynthesis, where a correspondence or deviation allows the authenticity or origin or adulteration of the substance to be detected.

Abstract: A chewing gum composition including an abrasive filler substance, the said abrasive filler substance being encapsulated in cross-linked alginate microspheres.

Abstract: A process for the preparation of the compounds of formula (wherein R has the meanings reported in the specification) by enzymatic transesterification of enantiomeric mixtures is described. These compounds are intermediates useful in the synthesis of Diltiazem.

Abstract: A process for the preparation of a saturated butanone having a terminal substituted aryl group (I) by the selective reduction of an aryl-substituted .alpha.,.beta.-unsaturated butanone (II) is presented. The aryl moiety can be mono- or polysubstituted by one or more C.sub.1 -C.sub.6 alkoxy, methylenedioxy or hydroxyl radicals and R is a C.sub.1 -C.sub.6 radical. The .alpha.,.beta.-unsaturated butanone (II) is subjected to the action of the enzymes of a yeast or of a filamentous fungus to give a mixture of (I) and an alcohol (III). (I) and (III) are isolated and purified. (III) can be enzymatically oxidized to provide (I).

Abstract: A method for the acylation of the 7-amino group of the cephalosporanic ring, according to which a 7-ACA amino thiazolyl protected adduct is prepared by acylating said amino group by an aminothiazolyl acetic acid whose amino group has been protected by a phenyl acetyl or a phenoxy acetyl group, the amino group being then deprotected by aqueous hydrolysis in the presence of penicillin G amidase or respectively penicillin V amidase.

Abstract: Gamma lactones with 9 carbon atoms, saturated or unsaturated and mixtures thereof, in natural form, are obtained by:A) culturing a microorganism selected from the group comprising Pichia ohmeri and Pichia stipitis or both of these in a substrate comprising an unsaturated C.sub.18 hydroxy-acid with the hydroxyl in position C.sub.13 to obtain a mixture comprising gamma nonanolide;or, alternatively,B) subjecting to lipoxygenation a substrate comprising an acid selected from the group comprising linoleic acid and linolenic acid or mixtures thereof anddistilling the product of lipoxygenation in a current of steam to obtain a mixture comprising an unsaturated gamma lactone that is gamma-2-nonenolide, gamma-2,6-nonadienolide or mixtures thereof.

Abstract: A process for the preparation of the compounds of formula ##STR1## (wherein R has the meanings reported in the specification) by enzymatic transesterification of enantiomeric mixtures is described.These compounds are intermediates useful in the synthesis of Diltiazem.

Abstract: The production of natural delta-decanolide and/or delta-dodecanolide or mixtures thereof, by means of the biohydrogenation of a substrate containing the corresponding unsaturated lactones, delta-decen-2-olide and delta-dodecen-2-olide, respectively, and mixtures thereof, is performed by means of the use of a microorganism chosen from the group consisting of Saccharomyces delbrueckii, Pichia ohmeri, Hansenula anomala, Pichia stipitis, Debaromyces hansenii, Zymomonas mobilis, Zygosaccharomyces rouxii, Schawnniomyces occidentalis, Sarcina lutea and Geotrichum candidum.